1. PRCA and Immunogenecity (Background)
   • PRCA and Immunogenecity
   
   
2. PRCA Patient Database Update
   • Patient Database Update
   • Dear Doctor: Important Update - Eprex (epoetin alfa) - Pure Red Cell Aplasia (PRCA, Erythroblastopenia)
   
   
3. CURRENT LITERATURE ON PRCA
   • European Best Practice Guidelines 9-13 Anaema Management
   • The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration ( i.v. or s.c. )
   • Human Response to Recombinant Human Proteins
   
   
4. Further Information
   • Further Information for Customers and Patients

  The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration ( i.v. or s.c. )

"No changes in rHuEpo dose were observed after cinversion from s.c. to i.v. There were no significant differences between the conversion and non-conversion group. These results are in contrast to some earlier studies suggesting lower rHuEpo requirements in case of s.c. administration."

Gert De Schoenmakere, Norbert Lameire, Annemieke Dhondt, et al
The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.)
Nephrology Dialysis Transplantation (1998) 13: 1770-1775